TABLE 3.

Salivary APAP pharmacokinetics and urinary APAP metabolite excretion by UGT2B15 genotypes

Data are least squares means ± S.E.

	UGT2B15*1/*1		UGT2B15*1/*2		UGT2B15*2/*2
	Basal	F&V	Basal	F&V	Basal	F&V
Salivary pharmacokinetics
n	16	16	33	33	17	17
Cmax (mg/l)	15.9 ± 1.2	17.0 ± 1.3	15.4 ± 0.8a	17.3 ± 0.9b	17.8 ± 1.3	18.1 ± 1.3
Clearance (1/h)	10.2 ± 1.0	10.3 ± 1.0	9.3 ± 0.6	9.5 ± 0.6	12.1 ± 1.1	10.4 ± 1.0
AUC (mg · min/l)	5913 ± 504	5787 ± 493	6473 ± 377	6494 ± 373	5426 ± 449	5738 ± 482
t1/2 (min)	307 ± 31†	282 ± 28	270 ± 18‡	290 ± 20	201 ± 19a,‡	268 ± 26b
Urinary APAP metabolite excretion
n	16	16	33	33	17	17
% of oral dose
%APAP	3.0 ± 0.2	2.9 ± 0.2	3.0 ± 0.1	3.2 ± 0.1	3.4 ± 0.2	3.5 ± 0.2
%APAPG	40.2 ± 1.6†	40.9 ± 1.6†	35.1 ± 1.1‡	36.0 ± 1.1‡	29.3 ± 1.5§	30.4 ± 1.5§
%APAPS*	22.1 ± 1.6a,†	19.0 ± 1.5b,†	23.3 ± 1.1a,‡	21.6 ± 1.1b,‡	28.5 ± 1.5a,§	26.9 ± 1.5b,§
Metabolite ratios
APAPG ratioc*	61.3 ± 1.8a,†	65.9 ± 1.8b,†	57.3 ± 1.2a,‡	59.4 ± 1.2b,‡	47.9 ± 1.7a,§	50.1 ± 1.8b,§
APAPG/APAP	13.9 ± 1.2†	15.5 ± 1.3†	12.2 ± 0.7‡	11.7 ± 0.7‡	8.9 ± 0.7§	9.0 ± 0.7§
APAPS/APAP*	7.6 ± 0.7a	6.8 ± 0.6b	8.0 ± 0.5a	6.8 ± 0.4b	8.7 ± 0.7	8.0 ± 0.7

^* Significant overall diet effect for UGT2B15 genotype (P < 0.05).

^†,‡,§ <ths>Different superscript numbers represent significant genotype differences within diet (P < 0.05).

^a,b Different superscript letters represent significant diet differences within a genotype (P < 0.05).

^c APAPG/(APAP + APAPG + APAPS) × 100.